September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Rising Risk for Leptomeningeal Metastases in NSCLC Patients with EGFR Mutations
August 18th 2016Leptomeningeal metastases are more common in patients with non–small cell lung cancer who harbor <em>EGFR </em>mutations. Tyrosine kinase inhibitors were found to be the optimal treatment method for these patients, especially if they have not yet received a TKI treatment.
Read More
The Ongoing Research on Bevacizumab in Non-Small Cell Lung Cancer
August 10th 2016Heather Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses the evolving role of bevacizumab (Avastin) in the treatment of patients with non–small cell lung cancer.
Watch
The Role of Plasma as a Potential Alternative to EGFR Mutation Analysis in NSCLC
August 4th 2016Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the recent data showing that plasma can act as a potential alternative to EGFR mutation analysis in the treatment of patients with non-small cell lung cancer, as well as the current demands for the use of liquid biopsies in this type of treatment.
Watch
New Targeted Treatments Gaining Recognition in NSCLC, Says Expert
August 1st 2016Although immunotherapies, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), have generated great excitement in the field of squamous non-small cell lung cancer, a number of targeted agents are also gaining recognition.
Read More
TKIs Competing for Frontline Therapy in ALK+ NSCLC
July 25th 2016Deciding the sequencing order of therapies for patients with ALK-positive non–small cell lung cancer (NSCLC) is a challenge, as new information on next-generation tyrosine kinase inhibitors (TKIs) comes to light, says Robert Doebele, MD, PhD. Testing for ALK translocations can help to determine which therapies NSCLC patients should be receiving, but questions regarding the sequencing of ALK inhibitors still remain.
Read More
Oxnard Explains Role of BRAF in NSCLC
July 8th 2016Geoffrey R. Oxnard, MD, specializes in researching molecular mutations in non-small cell lung cancer (NSCLC) with a particular emphasis on prognostic and predictive biomarkers. Oxnard spoke with Targeted Oncology about the potential for BRAF-targeting therapies in NSCLC.
Read More
The Ideal Patient Population for the Use of Nivolumab in Treatment of NSCLC
July 7th 2016Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the ideal patient population that can potentially benefit from the use of nivolumab in the treatment of non-small cell lung cancer.
Watch
Suggestion of Survival Benefit Persists with mTOR Inhibitor in Subset of NETs
June 18th 2016Patients with nonfunctioning neuroendocrine tumors of gastrointestinal or lung origin continued to live longer when treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus than with placebo, ongoing follow-up in a randomized trial showed.
Read More
Plasma Tests Can Complement Tissue Assays in Screening for Drug Resistance Mutation
June 10th 2016Plasma and urine tests are often a reliable method for the detection of the T790M mutation in non-small cell lung cancer (NSCLC) patients with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs), according to an oral presentation given Monday at the 2016 ASCO Annual Meeting in Chicago.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
Third-Generation EGFR TKI Shows Preliminary Efficacy for Leptomeningeal Disease in NSCLC
June 8th 2016The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) demonstrated promising activity in a phase I study of heavily pretreated patients with advanced non-small cell lung cancer (NSCLC) and leptomeningeal disease who harbor activating EGFR mutations.
Read More
Sustained Survival Shown in Updated Nivolumab Results in NSCLC
June 7th 2016Updated findings from the phase III CheckMate-057 and -017 trials showed sustained improvements in overall survival (OS) data of nivolumab (Opdivo) treatment in pretreated patients with nonsquamous or squamous non-small cell lung cancer (NSCLC).
Read More
Rovalpituzumab Tesirine Single-Agent Activity and Safety Profile Prove Positive in SCLC
June 7th 2016Treatment with the delta-like protein 3 (DLL3)-targeted antibody-drug conjugate rovalpituzumab tesirine demonstrated single-agent activity and a manageable safety profile for patients with recurrent/refractory SCLC.
Read More
Brain Metastases Do Not Influence Outcome in Patients with Mutated NSCLC
June 6th 2016The number of brain metastases does not have an impact on overall survival (OS) in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation or ALK rearrangement, Cleveland Clinic investigators discovered.
Read More
Differences Between CDK4&6 Inhibitors Predict Future Approaches
May 28th 2016Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors are a promising class of anticancer agents that may present effective alternatives to standard therapy for women with advanced, refractory, or relapsed hormone receptor (HR)‒positive breast cancer.
Read More